Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 7,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Phase 2 Interventional Results available

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Adjuvant endocrine therapy, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
33
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer

NCT03262831
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast
Interventions
Yoga, Blood draw, FACT-G questionnaire, Weight measurement, Recent Physical Activity Questionnaire, NHANES Food Questionnaire
Other · Procedure · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Phase 2 Interventional

Proton Radiation for Stage II/III Breast Cancer

NCT01758445
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions
Proton Radiotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
5
States / cities
Warrenville, Illinois • Baltimore, Maryland • Somerset, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Recruiting Phase 1 Interventional

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

NCT05627960
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions
AG-01 Compound
Drug
Lead sponsor
A&G Pharmaceutical Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Exercise Program for Early Breast Cancer Survivors

NCT01140282
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
questionnaire administration, quality-of-life assessment, management of therapy complications, exercise intervention
Other · Procedure · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT02441946
View directory record Official record
Conditions
Breast Cancer, Hormone Receptor Positive Tumor, Early-Stage Breast Carcinoma
Interventions
Abemaciclib, Loperamide, Anastrozole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Bakersfield, California • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 30, 2026, 9:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

NCT00823654
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw and questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
609 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, lapatinib plus esomeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 30, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

NCT00617929
View directory record Official record
Conditions
Cancer
Interventions
anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Disitamab vedotin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
128
States / cities
Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

NCT05488483
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Multispectral Optoacoustic Tomography Imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Montvale, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Non-Invasive Imaging for Cording in Breast Cancer Patients

NCT01427166
View directory record Official record
Conditions
Breast Cancer
Interventions
Non invasive venous ultrasound
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 30, 2026, 9:37 PM EDT
Completed No phase listed Observational

An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

NCT00291122
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib 400 mg BID
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

NCT03428802
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions
Laboratory Biomarker Analysis, Pembrolizumab
Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain

NCT02439437
View directory record Official record
Conditions
Breast Cancer
Interventions
Psychosocial Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Not applicable Interventional

Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study

NCT05327452
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Supervised Home-Based Exercise, Unsupervised Home-Based Exercise, Attention Control
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

NCT03200704
View directory record Official record
Conditions
Breast Cancer, Lymph Node Mapping, Sentinel Lymph Node Biopsy
Interventions
IC2000 and SPY-PHI, Tc-99m radioactive colloid and Gamma Probe
Combination Product
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 30, 2026, 9:37 PM EDT
Recruiting Phase 2 Interventional

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

NCT06105684
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine Pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Recruiting Not applicable Interventional

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

NCT05667532
View directory record Official record
Conditions
Breast Cancer
Interventions
Contrast Enhanced Mammography
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer

NCT00005963
View directory record Official record
Conditions
Breast Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
21
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 30, 2026, 9:37 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
13
States / cities
Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 30, 2026, 9:37 PM EDT